Latest Regulatory Milestones News

Compumedics has secured FDA clearance for its single-use Somfit®D device, effectively doubling its addressable U.S. home sleep testing market to an estimated US$240 million annually. This milestone positions the company to capture significant market share with a dual-platform EEG-based solution.

Beetaloo Energy is gearing up for first gas production in 2026 from its Carpentaria Pilot Project, backed by a $65 million financing package and a binding 10-year gas sales agreement with the Northern Territory government.

Brazilian Rare Earths Limited has obtained the final regulatory approval to operate its rare earth pilot plant in Brazil’s largest petrochemical complex, setting the stage for pilot operations in mid-2026.

VRX Silica Limited has obtained crucial environmental approval for its Arrowsmith North Silica Sand Project, paving the way for binding contracts and first production targeted in late 2026.

Tamboran Resources has secured a pioneering approval from the Northern Territory Government to sell appraisal gas from its Beetaloo Basin exploration permits, marking a significant step toward local energy supply and revenue generation.

Buru Energy has successfully raised $2.1 million through a share placement and launched a $3 million Share Purchase Plan to advance its Rafael Gas Project, targeting a Final Investment Decision by late 2026 and first cash flow by early 2028.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

HALO Technologies reports a significantly improved half-year net loss and secures verbal FCA approval for its UK platform, while preparing to launch Managed Funds in Australia.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.